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With the clinical demonstration of the efficacy of immune checkpoints inhibitors, immunotherapy
has been considered in 2013 to be the major breakthrough for cancer therapy (Couzin-Frankel,
2013). Cell therapy and adoptive cell therapy (ACT), a method based on administration of
immunocompetent cells in order to induce a therapeutic response in patients with solid cancer,
hematologic malignancies, or immune diseases, have been widely and successfully tested in
clinic for the past few years (Rosenberg and Restifo, 2015). Allogeneic hematopoietic stem cell
transplantation (HSCT) is themost potent and consolidated ACT approach for the immunotherapy
of hematologic malignancies (Tsirigotis et al., 2014). Alternative ACT approaches rely on the
selection, expansion and possibly gene modification of autologous or allogeneic immune cells, such
as regulatory or effector T cells, NK cells, or dendritic cells. Chimeric antigen receptor (CAR)-T cells
transfer is a very promising therapy. CARs are antigen-binding domains linked to T-cell signaling
domains, allowing for a specific recognition of cell surface antigens independently of the Major
Histocompatibility Complex. Many clinical trials have demonstrated the efficiency of genetically
modified T cells (GMCs) to treat cancers, including CAR-T cells. However, severe side effects of
allogeneic HSCT or ACT, including the induction of graft-vs.-host disease (GvHD) or on target,
off tumor effects limit the use of ACT, prompting researches to improve the safety of cell therapy
products.
Suicide gene therapy was initially developed with the aim of introducing in cancer cells a gene
whose activation by a prodrug would provide a toxic effect toward target cells and surrounding
cancer cells, an approach beyond the scope of this Research Topic. The proof-of-concept of the
transfer of a suicide gene (encoding the Herpes Simplex virus thymidine kinase, HSV-tk), not
directly in cancer cells but into donor T cells, prior allogeneic HSCT, in order to control their
alloreactivity was first described in 1994 (Tiberghien et al., 1994). Since then, clinical trials have
demonstrated the feasibility of this approach. Several suicide systems have been developed to secure
cell therapy and anti-tumor immunotherapy approaches in order to avoid adverse events. In this
context, the aim of this Research Topic in Frontiers is to provide a state of the art of available tools
to secure cell therapy products.
Jones et al. (2014) present different suicide gene families and summarize clinical results obtained
to date. Suicide genes are classified according to the mechanism of action developed: mAb-
mediated, such as CD20 antibody, metabolic withHSV-tk and dimerization-induced with inducible
Caspase-9 (iCasp9). HSV-tk has been clinically validated in allogeneic HSCT in order to kill T cells
in case of GvHD, by administration of its prodrug, ganciclovir (GCV). Briefly, GCV treatment
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resulted in significant reduction in the number of circulating
GMCs with no acute toxicity. Some disadvantages appeared such
as elimination of GMCs in several days, an immunogenicity
of non-human transgene, a possible interference of GCV as
antiviral in case of Cytomegalovirus (CMV) reactivation. So,
alternative suicide genes have be proposed in order to decrease
immunogenicity and to accelerate GMC elimination. Brenner
and collaborators developed the iCasp9 suicide gene. Its prodrug,
AP1903, a synthetic and non-toxic ligand, leads to iCasp9
dimerization and triggering of apoptotic pathway (Tey et al.,
2007). This system allows rapid and specific GMCs’ elimination
and is currently tested in clinical trials. To date, the iCasp9
remain one of the most promising suicide gene secure system.
Another interesting suicide gene is the human CD20, a B-cell
membrane marker that can be used both as a selection marker,
allowing for the immunomagnetic sorting of transduced cells and
as a suicide gene, through the in vivo depletion of CD20-positive
cells with CD20 monoclonal antibodies, such as Rituximab.
Respective pros and cons of each approach are presented by Jones
et al.
The first suicide gene historically clinically used for ACT
was the HSV-tk gene (Bonini et al., 1998; Tiberghien et al.,
2001). The group of Bordignon and Bonini, in Milano, has the
greatest clinical experience of HSV-tk GMCs infusion. Their
major contribution in the field of suicide gene therapy after
allogeneic HSCT is presented by Greco et al. (2015). The Milano
group developed Herpes Simplex Virus thymidine Kinase (HSV-
tk) suicide gene, strategy, and application and demonstrated
(i) the possibility to control T-cell alloreactivity after allogeneic
HSCT by infusion of ganciclovir (GCV), (ii) the ability of
GMCs to provide an anti-leukemic effect and (iii) their ability
to improve post-transplant immune cell reconstitution, while
preserving their protective functions toward viral and bacterial
infections. Their clinical trials involved several Europeans teams,
including the one of Weissinger et al. who, in their paper
(Weissinger et al., 2015), present the long term follow up of
patients after transfusion of HSV-TK transduced T-cells in the
context of allogenic HSCT. Clinical trials have been done between
2002 and 2007. Patients who developed a GvHD have been
successfully treated with GCV and they did not observe non-
functional HSV-tk gene. Today, some patients are still alive but
no HSV-tk expression was detected in these patients. These
studies demonstrated safety, efficacy and feasibility of using HSV-
tk GMCs. Although major contributions have been provided
by clinical trials using HSV-tk-engineered T cells, a major issue
remaining to be solved is related to the monitoring of GMCs
in patients. In this article, Eissenberg et al. (2014) suggest
to use HSV-tk for monitoring functions in order to localize
GMCs. Using 18F-9-(4-fluoro-3-hydroxymethylbutyl) guanine
(18FHBG), it is possible to follow and monitor GMCs with
PET/CT scans in order to know if cells reach their target.
Given the limitations of the HSV-tk/GCV system, a second
generation of suicide gene has recently emerged, whose leader
is the iCaps9. As noticed by Gargett and Brown, CAR therapy
show promising results due to partial or complete remissions
observed upon infusion of CD19 CAR T-cells to patients with
B-cell malignancies or after GD2 specific T-cell administration
to patients with neuroblastoma (Gargett and Brown, 2014).
Over 83 clinical trials using CAR T cells have been registered
(www.clinicaltrials.gov). However, many serious adverse events
such as cytokine storm and death can occur and have been
reported. These problems are independent of the number of
co-stimulatory domains and some of them are already known
with chemotherapy and targeted therapies. However, today, it
is necessary to improve the safety of cellular therapy products
in general and particularly of CAR T cells. As presented by
Gargett and Brown, the iCasp9 approach is a highly promising
approach offered for securing CAR T cells. The association
of CAR gene transfer with suicide gene transfer into T
cells is currently reaching clinical application, but a similar
approach on NK cells is still in preclinical development. To
finish, Glienke and collaborators investigated CAR therapy in
NK cells and the necessity to use suicide switches (Glienke
et al., 2015). A lot of cancer antigens are targeted by CAR
T cells in clinical trials. However, authors highlight the use
of genetically modified NK cells with CAR, due to advantages
of NK cells. Today, only two clinical studies are evaluating
CAR-expressing NK cells. In this paper, they also noticed the
importance to use suicide gene in order to secure NK-cell
therapies.
As a conclusion, use of suicide system to secure new cell
therapies, especially for those using gene-modified cells, is an
important approach in order to improve cell therapy safety
and decrease adverse effects. This Research Topic show that
many improvements have been obtained during suicide gene
development and that this technology has reached amaturity that
should allow now considering more systematically its use when
developing innovative cell therapies, including not only ACT, but
also induced pluripotent stem cells- or mesenchymal stem cell
based therapies.
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